Catheter Ablation for Brugada Syndrome

Area of Science:

• Cardiology
• Electrophysiology
• Genetics

Background:

• Brugada syndrome (BrS) is a genetic arrhythmogenic disorder predisposing individuals to ventricular fibrillation (VF) and sudden cardiac death (SCD).
• Current standard therapy involves implantable cardioverter-defibrillators (ICDs) for SCD prevention, which react to VF events rather than prevent them.
• Antiarrhythmic drugs are often used for recurrent VF but are associated with significant adverse effects.

Purpose of the Study:

• To evaluate catheter ablation as an alternative therapy for Brugada syndrome patients experiencing recurrent ventricular fibrillation.
• To highlight the advancements and effectiveness of epicardial substrate ablation in managing BrS.

Main Methods:

• Review of case series and clinical data on catheter ablation for Brugada syndrome.
• Focus on epicardial substrate ablation techniques implemented since 2011.

Main Results:

• Catheter ablation has demonstrated effectiveness in eliminating the premature ventricular complexes that trigger VF in BrS patients.
• Epicardial substrate ablation has shown significant progress and is now widely applicable for BrS management.

Conclusions:

• Catheter ablation, particularly epicardial substrate ablation, represents a promising and increasingly effective therapeutic option for Brugada syndrome.
• This approach offers an alternative to ICDs and antiarrhythmic drugs for preventing life-threatening arrhythmias in BrS.